Yakult Honsha Co.,Ltd.
2267
Rang in aandelen
#3385
Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the... Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the manufacturing and sale of a broad array of products, including food and beverages, cosmetics, and pharmaceuticals. The company's operations are segmented geographically for its Food and Beverages division, covering Japan, the Americas, Asia and Oceania, and Europe, alongside dedicated Pharmaceutical and "Others" segments. Its extensive food and beverage offerings feature popular items such as fermented milk beverages, various juices, and noodle products, which are distributed through both a home delivery service and traditional retail channels. In the pharmaceutical sector, Yakult Honsha provides specific medications like the antineoplastic drug Elplat, along with a suite of generic anti-cancer treatments, including Gemcitabine Yakult, Capecitabine, and Gefitinib Yakult tablets. Furthermore, the company maintains a presence in the cosmetics industry and is notably the owner of the professional baseball team, the Tokyo Yakult Swallows. Founded in 1935, Yakult Honsha Co.,Ltd. is headquartered in Tokyo, Japan.
Aandeelprijs
$17.80
Marktkapitalisatie
$5.12B
Verandering (1 dag)
-0.04%
Verandering (1 jaar)
11.52%
Land
JP
Handel Yakult Honsha Co.,Ltd. (2267)
Categorie
Consumer Defensive
Winst voor Yakult Honsha Co.,Ltd. (2267)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Yakult Honsha Co.,Ltd. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Yakult Honsha Co.,Ltd. van 2026 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $17.23B | - |
US
|
|
| $13.73B | - |
US
|
|
| $2.78B | - |
US
|
|
| $3.25B | - |
CN
|
|
| $1.97B | - |
US
|
